AAMU
AKCA

Amundi Asset Management US’s Akcea Therapeutics Inc AKCA Stock Holding History

Amundi Asset Management US’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9,700
Closed -$164K – 1699
2019
Q4 		$164K Hold
9,700
– – ﹤0.01% 1511
2019
Q3 		$149K Buy
+9,700
New +$207K ﹤0.01% 1518

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Amundi Asset Management US's AKCA Position: Q1 2020 in Review

Amundi Asset Management US sold out of Akcea Therapeutics Inc (AKCA) in Q1 2020, closing a stake of 9,700 shares — an estimated $164K sold.

Amundi Asset Management US first reported a position in AKCA in Q3 2019 and held it in 2 quarters. The position peaked at $164K in Q4 2019. 77 funds tracked by Wall St. Rank hold AKCA as of Q1 2020.

  • Amundi Asset Management US reported no remaining Akcea Therapeutics Inc position as of Q1 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 9,700 Akcea Therapeutics Inc shares in Q1 2020, an estimated $164K.
  • Amundi Asset Management US first reported a position in Akcea Therapeutics Inc in Q3 2019 and held it in 2 quarters.
  • Amundi Asset Management US's Akcea Therapeutics Inc position peaked at $164K in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2020.

Based on Amundi Asset Management US's 13F filing for Q1 2020, filed 15 May 2020.